background
sever
acut
respiratori
syndrom
sar
novel
infecti
diseas
inform
current
avail
hostspecif
immun
sar
coronaviru
cov
detail
characterist
epidemiolog
sar
cov
infect
identifi
method
elisa
use
detect
antibodi
sar
cov
reversetranscriptas
polymeras
chain
reaction
use
detect
sar
cov
rna
cell
peripher
blood
patient
quantifi
flow
cytometri
result
patient
probabl
sar
cov
infect
posit
igg
antibodi
sar
cov
contrast
patient
suspect
sar
cov
infect
patient
fever
without
sar
healthi
control
individu
posit
igg
antibodi
sar
cov
first
detect
day
day
onset
ill
mean
sd
conclus
detect
antibodi
sar
cov
use
diagnosi
sar
howev
incub
initi
phase
ill
serolog
assay
littl
valu
late
seroconvers
patient
sever
acut
respiratori
syndrom
sar
novel
infecti
diseas
global
impact
sinc
novemb
outbreak
sar
affect
countri
contin
report
case
death
time
world
health
organ
report
publish
viru
famili
coronavirida
term
sar
coronaviru
sar
cov
identifi
caus
criteria
laboratori
confirm
sar
cov
infect
provid
basi
follow
method
detect
sar
cov
rna
reversetranscript
polymeras
chain
reaction
rtpcr
serolog
detect
sar
covrel
antibodi
isol
sar
cov
cell
cultur
thu
investig
profil
implic
presenc
specif
antisar
cov
antibodi
would
like
provid
inform
would
benefici
diagnost
confirm
exclus
sar
case
could
function
valuabl
indic
use
analysi
hostspecif
immun
sar
cov
charact
sar
cov
infect
immunolog
characterist
sar
cov
infect
yet
fulli
understood
short
span
time
sinc
outbreak
sar
unavail
tool
detect
reagent
use
indirect
immunofluoresc
assay
parallel
acut
convalesc
serum
sampl
obtain
patient
sar
test
igg
antibodi
sar
cov
peiri
et
al
recent
document
seroconvers
igg
antibodi
patient
mean
day
result
peiri
et
al
studi
prompt
us
studi
serolog
humor
immun
sar
cov
infect
gain
comprehens
understand
antibodi
sar
cov
addit
clarif
would
gain
moredetail
profil
igg
igm
antibodi
sar
cov
conveni
assay
elisa
requir
also
sought
determin
implic
antibodi
profil
includ
present
studi
patient
probabl
sar
cov
infect
patient
suspect
sar
cov
infect
sar
diagnos
basi
case
definit
provid
also
includ
studi
patient
fever
without
sar
admit
hospit
studi
time
frame
addit
healthi
individu
healthcar
worker
includ
control
patient
fever
without
sar
upperrespiratorytract
infect
pneumonia
influenza
pulmonari
tuberculosi
individu
control
group
consist
physician
nurs
came
close
contact
patient
sar
routin
underw
isol
procedur
prior
contact
patient
control
individu
particip
present
studi
neg
hiv
characterist
studi
particip
shown
tabl
patient
control
individu
inform
purpos
procedur
content
clinic
studi
clinic
sampl
obtain
given
written
inform
consent
obtain
clinic
specimen
serum
nasopharyng
aspir
fece
whole
blood
patient
probabl
sar
cov
infect
patient
suspect
sar
cov
serum
sampl
obtain
everi
day
first
month
patient
admiss
hospit
thereaft
everi
week
day
onset
fever
sampl
nasopharyng
aspir
fece
obtain
day
ie
day
admiss
day
patient
admiss
whole
blood
measur
cell
obtain
day
patient
fever
without
sar
serum
sampl
obtain
day
sampl
nasopharyng
aspir
fece
day
sampl
whole
blood
day
control
group
serum
sampl
obtain
day
first
contact
patient
sar
sampl
nasal
swab
sampl
fece
obtain
day
complet
sar
cov
particl
purifi
supernat
sar
covinfect
vero
cell
cultur
use
antigen
detect
igg
igm
antibodi
sar
cov
use
elisa
kit
jibiai
biotech
serum
sampl
store
elisa
sampl
perform
parallel
procedur
interpret
result
strictli
follow
elisa
supplier
instruct
total
rna
extract
clinic
sampl
describ
elsewher
use
commerci
rnaextract
kit
brief
qiaamp
viral
rna
mini
kit
qiagen
use
sampl
na
sal
swab
sampl
nasopharyng
aspir
qiaamp
stool
kit
qiagen
use
sampl
fece
nest
rtpcr
ml
total
rna
obtain
clinic
sampl
revers
transcrib
use
oligonucleotid
nt
cdna
amplifi
use
outer
primer
nt
nt
subsequ
use
inner
primer
nt
nt
realtim
quantit
rtpcr
assay
perform
describ
elsewher
use
commerci
kit
realart
hpacoronaviru
lc
rtpcr
reagent
roch
biomed
laboratori
rtpcr
perform
lightcycl
roch
biomed
laboratori
accord
manufactur
instruct
sampl
posit
sar
cov
rna
confirm
direct
dna
sequenc
use
dna
sequenc
analyz
abi
appli
biosystem
indic
nucleotidesequ
align
sar
cov
sequenc
publish
genbank
access
number
brief
sampl
whole
blood
collect
edta
immunolabel
monoclon
antibodi
immunotech
room
temperatur
mous
mous
mous
immunotech
incub
isotyp
control
allow
subtract
nonspecif
stain
red
blood
cell
lyse
min
room
temperatur
use
ml
optilys
c
immunotech
cell
wash
time
ml
pb
resuspend
flowcytometri
analysi
use
coulter
epic
xl
beckmancoult
statist
analysi
continu
variabl
compar
student
test
correl
assess
pearson
correl
analysi
use
softwar
program
spss
version
consid
statist
signific
p
product
igg
igm
antibodi
sar
cov
seen
earli
day
day
respect
onset
fever
patient
probabl
sar
cov
infect
produc
antisar
cov
antibodi
day
produc
day
figur
patient
suspect
sar
cov
infect
posit
igg
antibodi
sar
cov
posit
igm
antibodi
sar
cov
sar
cov
sequenc
publish
genbank
access
number
moreov
sampl
posit
sar
cov
rna
confirm
realtim
pcr
indic
viral
load
copiesml
patient
suspect
sar
cov
infect
patient
fever
without
sar
control
individu
posit
sar
cov
rna
addit
differ
amount
antisar
cov
antibodi
produc
patient
posit
sar
cov
rna
produc
patient
neg
sar
cov
rna
relationship
product
igg
antibodi
sar
cov
cell
immun
quantifi
cell
cell
peripher
blood
patient
probabl
sar
cov
infect
suspect
sar
cov
infect
result
indic
patient
experienc
dramat
decreas
cell
percentag
mean
sd
cell
percentag
mean
sd
compar
patient
fever
without
sar
p
whose
mean
sd
cell
percentag
cell
percentag
respect
tient
probabl
sar
cov
infect
signific
differ
cell
percentag
posit
igg
antibodi
sar
cov
mean
sd
neg
mean
sd
howev
signific
p
ferenc
found
cell
percentag
group
tabl
also
patient
probabl
sar
cov
infect
signific
differ
either
cell
percentag
posit
igm
antibodi
sar
cov
neg
correl
found
day
igg
p
antibodi
seroconvers
cell
percentag
measur
day
patient
admiss
hospit
assum
day
day
r
p
p
seroconvers
patient
actual
seroconvert
much
progress
made
sar
research
includ
identif
etiolog
agent
complet
sequenc
sar
cov
genom
establish
diagnost
laboratori
method
rtpcr
indirect
immunofluoresc
assay
establish
measur
prevent
sar
manag
probabl
sar
case
howev
still
uncertain
whether
sar
recurr
impact
recurr
might
inform
statu
hostspecif
immun
sar
cov
detail
characterist
epidemiolog
sar
cov
infect
known
given
uncertain
background
investig
potenti
signific
clinic
implic
profil
antisar
cov
antibodi
differ
popul
includ
patient
probabl
sar
cov
infect
patient
suspect
sar
cov
infect
patient
fever
without
sar
healthi
control
individu
healthcar
worker
came
close
contact
patient
sar
result
investig
presenc
antisar
cov
antibodi
patient
either
probabl
suspect
sar
cov
infect
show
use
elisa
detect
igg
antibodi
andor
igm
antibodi
sar
cov
specif
use
method
diagnosi
sar
especi
given
elisa
sensit
detect
antisar
cov
antibodi
much
better
rtpcr
sensit
detect
sar
cov
rna
studi
serolog
assay
howev
littl
valu
incub
initi
phase
ill
late
seroconvers
patient
figur
addit
result
indic
patient
probabl
sar
cov
infect
produc
detect
antisar
cov
antibodi
day
onset
fever
impli
patient
sar
might
misdiagnos
laboratori
confirm
guidelin
current
recommend
howev
case
studi
patient
later
confirm
detect
seroconvers
day
infect
sar
cov
patient
remain
neg
antisar
cov
antibodi
day
later
confirm
fulfil
criteria
exclus
pathogen
infect
infect
sar
cov
specif
patient
probabl
sar
cov
infect
came
contact
someon
sar
document
persist
fever
show
consist
clinic
cours
ill
ness
show
evid
pneumonia
plain
radiographi
andor
comput
tomographi
addit
evid
infect
pathogen
includ
influenza
virus
b
human
parainfluenza
virus
respiratori
syncyti
viru
adenoviru
chlamdia
pneumonia
c
psittaci
mycoplasma
pneumonia
mycobacterium
tuberculosi
convent
pathogen
bacteri
infect
respons
antibiot
treatment
g
levofloxacinday
h
discrep
diagnosi
sar
patient
diagnosi
basi
guidelin
like
reflect
evolut
identif
definit
sar
case
data
diseas
accumul
current
guidelin
probabl
accur
notabl
juli
center
diseas
control
prevent
revis
laboratori
criteria
definit
sar
requir
convalesc
serum
collect
day
instead
day
onset
symptom
choic
day
presum
reflect
data
indic
patient
sar
mount
detect
convalesc
antibodi
respons
technic
explan
identif
lateseroconvert
patient
may
involv
differ
sensit
elisa
use
present
studi
sensit
serolog
assay
guidelin
base
issu
clarifi
data
collect
patient
late
antibodi
respons
may
mitig
factor
could
led
decreas
basic
immun
patient
old
emphysema
diabet
hypertens
coronari
arteri
diseas
tetanu
pregnant
condit
may
associ
late
seroconvers
patient
notabl
patient
probabl
sar
cov
infect
posit
igg
antibodi
sar
cov
day
neg
igm
antibodi
sar
cov
reason
uncertain
one
possibl
explan
case
igm
antibodi
sar
cov
persist
short
time
disappear
patient
admit
hospit
found
product
igg
antibodi
sar
cov
associ
host
cell
immun
patient
produc
igg
antibodi
sar
cov
significantli
lower
cell
percentag
compar
patient
seroconvert
addit
day
igg
antibodi
seroconvers
correl
cell
percentag
taken
day
patient
admiss
r
p
p
result
suggest
product
igg
antibodi
sar
cov
depend
cell
appear
igg
antibodi
sar
cov
might
indic
product
protect
immun
sar
cov
recent
treat
pregnant
patient
sever
sar
cov
infect
use
convalesc
plasma
titer
igg
antibodi
sar
cov
igg
antibodi
could
detect
day
infus
day
igg
antibodi
sar
cov
appear
combin
treatment
antivir
drug
methylprednisolon
convalesc
serum
recov
fulli
howev
whether
igg
antibodi
sar
cov
neutral
antibodi
need
studi
recent
krokhin
et
al
report
acut
earli
convalesc
serum
obtain
sever
patient
recov
sar
react
nucleoprotein
appear
major
antigen
sar
cov
result
suggest
immun
respons
nucleoprotein
could
serv
earli
diagnost
indic
infect
howev
unlik
immun
respons
protein
offer
protect
intern
protein
neutral
antibodi
like
target
cellsurfac
protein
nevertheless
shown
cov
antigen
peptid
nucleoprotein
recogn
surfac
infect
cell
host
cell
thu
appear
igg
antibodi
patient
sar
like
indic
product
protect
immun
sar
cov
result
also
indic
individu
posit
antisar
cov
antibodi
present
symptom
whether
sever
feb
time
articl
written
hospit
admit
patient
probabl
sar
cov
infect
patient
suspect
sar
cov
infect
howev
hospit
singl
healthcar
worker
infect
sar
cova
situat
stark
contrast
hospit
china
nearli
onethird
patient
sar
healthcar
worker
hospit
healthcar
worker
infect
sar
cov
confirm
serolog
assay
lack
detect
sar
cov
rna
healthcar
worker
particip
studi
came
close
contact
patient
sar
period
month
igg
igm
antibodi
sar
cov
detect
serum
healthcar
worker
result
may
somewhat
difficult
interpretand
certainli
point
studi
investig
matterbut
implic
may
import
suggest
possibl
peopl
asymptomat
infect
sar
covand
individu
exist
transmit
virusmight
small
prevent
measur
taken
hospit
almost
exactli
taken
hospit
known
differ
prophylaxi
healthcar
worker
hospit
took
mg
ribavirin
day
must
caution
howev
anecdot
observ
studi
necessari
determin
whether
ribavirin
prophylact
effect
sar
cov
infect
